Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare and orphan diseases. The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803. It is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset stills disease and multiple myeloma, as well as for the treatment of systemic juvenile idiopathic arthritis; CERC-006, an oral mTORC1/2 inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody that is in phase 2 clinical trial for the treatment of COVID-19 acute respiratory distress syndrome, as well as for the treatment of pediatric-onset Crohn's diseases. In addition, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. Cerecor Inc. has a collaboration agreement with The Frontiers in Congenital Disorders of Glycosylation Consortium on pivotal trial of CERC-801 for the treatment of Phosphoglucomutase-1 deficiency related congenital disorders of glycosylation. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
IPO Year: 2015
Exchange: NASDAQ
Website: cerecor.com
Positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatmentsMean reduction in LIGHT levels of approximately 80% compared to baseline signify a dramatic and rapid reduction of LIGHT levels correlating to the pharmacodynamic effect of CERC-002Clinically meaningful endoscopic improvement in 75% (3/4) of subjects, as determined by colonoscopy (SES-CD score)CERC-002 was well tolerated with no drug-related severe adverse eventsCohort 2 (3.0 mg/kg dose) fully enrolled; complete data anticipated in 2H21Promising initial results support expansion to p
MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced the appointment of Garry A. Weems, PharmD, as its Vice President of Clinical Development and Medical Affairs. Dr. Weems joins Panbela from Cerecor, Inc. (Nasdaq:CERC) where he was Senior Director of Clinical Development. “Panbela has made considerable progress in the last 12-months and is now at a critical juncture as we begin to plan more expansive development of SBP-101,” said Jennifer Simpson, Chief Executive Officer at Panbela. “Garry’s substantial backgroun
ROCKVILLE, Md. and CHESTERBROOK, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced the appointment of Schond L. Greenway as Chief Financial Officer, effective March 1, 2021. Mr. Greenway comes to Cerecor with over 20 years’ experience in investment banking, finance and corporate advisory and investment analysis in the life sciences and financial services industries. Chris Sullivan, who has served as the Company’s Interim Chief Financial Officer for the past year, will continue with the Company as its Chief Accounting
SC 13D/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)
SC 13D/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
SC 13G - Cerecor Inc. (0001534120) (Subject)
Cantor Fitzgerald initiated coverage of Cerecor with a rating of Overweight and set a new price target of $7.00
Maxim Group upgraded Cerecor from Hold to Buy and set a new price target of $7.00
Jefferies initiated coverage of Cerecor with a rating of Buy and set a new price target of $4.00
Name change underscores the Company's transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic diseasesRobust pipeline of six product candidates advancing in development with eight ongoing clinical programsFour therapies with Rare Pediatric Disease Designation with each potentially eligible for a Priority Review Voucher upon approvalMultiple data readouts anticipated in the second half of 2021 WAYNE, Pa. and ROCKVILLE, Md., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significa
Announced positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate-to-severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatmentsAnnounced plans to explore CERC-002 in patients with moderate-to-severe ulcerative colitis refractory to anti-TNF alpha therapiesCompleted $35 million debt financing that extends cash runway and supports multiple clinical catalysts anticipated in the second half of 2021 ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of tre
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced that it has completed its second drawdown of $10 million under its previously announced $35 million debt financing agreement with Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon"). This second tranche was made available in connection with the Company's successful positive initial results from a Phase 1b proof-of-concept study evaluating CERC-002, an investigational first-in-class fully huma
Positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatmentsMean reduction in LIGHT levels of approximately 80% compared to baseline signify a dramatic and rapid reduction of LIGHT levels correlating to the pharmacodynamic effect of CERC-002Clinically meaningful endoscopic improvement in 75% (3/4) of subjects, as determined by colonoscopy (SES-CD score)CERC-002 was well tolerated with no drug-related severe adverse eventsCohort 2 (3.0 mg/kg dose) fully enrolled; complete data anticipated in 2H21Promising initial results support expansion to p
ROCKVILLE, Md., June 23, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunology, immuno-oncology and rare genetic disorders, today announced that it has entered into an exclusive license agreement with Sanford Burnham Prebys for the worldwide development and commercialization of an immune checkpoint program. The acquisition further enhances the Company's development pipeline of novel biologics that address immunology and immuno-oncology targets. "We are delighted to enter into this license agreement with Sanford Burnham Prebys," said Garry Neil, Chief Scientific Off
ROCKVILLE, Md. and CHESTERBROOK, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced that members of its senior management team will participate in three upcoming virtual investor conferences. 2021 RBC Capital Markets Global Healthcare Virtual Conference Date: Tuesday, May 18, 2021Time: 8:35 AM ET Oppenheimer Rare & Orphan Disease SummitDate: Friday, May 21, 20211x1 meetings only Jefferies Virtual Healthcare ConferenceDate: Wednesday, June 2, 2021Time: 1:00 PM ET A live webcast of the presentation at the 2021 RBC Cap
ROCKVILLE, Md. and CHESTERBROOK, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CERC-002 for treatment of hospitalized patients with COVID-19. CERC-002 is a first-in-class fully human monoclonal antibody targeting LIGHT (tumor necrosis factor superfamily member 14, TNFSF14). Fast Track designation is granted to drugs being developed for the treatment of serious or life-threatening diseases or conditions where there is an unmet medica
Initial data anticipated in the third quarter of 2021Top-line data from the ongoing Phase 1b proof of concept clinical trial in relapsed or refractory multiple myeloma patients anticipated in the second half of 2021 ROCKVILLE, Md. and CHESTERBROOK, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that it has dosed its first patient in a Phase 1b open-label dose-escalation clinical trial of CERC-007 in patients with adult onset Still's disease (AOSD). The Company anticipates initial data to be reported in the thir
Expanded agreement for exclusive, world-wide rights to develop, manufacture and commercialize CERC-002 for all indications including severe pediatric onset inflammatory bowel disease and ARDS (including COVID-19 ARDS)Kyowa Kirin Co. has an option to retain the rights for all indications in Japan ROCKVILLE, Md., March 29, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced that its wholly-owned subsidiary, Aevi Genomic Medicine, LLC (“Cerecor”), has entered into an expanded agreement with Kyowa Kirin Co., for exclusive worldwide ri
MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced the appointment of Garry A. Weems, PharmD, as its Vice President of Clinical Development and Medical Affairs. Dr. Weems joins Panbela from Cerecor, Inc. (Nasdaq:CERC) where he was Senior Director of Clinical Development. “Panbela has made considerable progress in the last 12-months and is now at a critical juncture as we begin to plan more expansive development of SBP-101,” said Jennifer Simpson, Chief Executive Officer at Panbela. “Garry’s substantial backgroun
8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
424B5 - Avalo Therapeutics, Inc. (0001534120) (Filer)
424B5 - Avalo Therapeutics, Inc. (0001534120) (Filer)
8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
8-K - Cerecor Inc. (0001534120) (Filer)
8-K - Cerecor Inc. (0001534120) (Filer)
8-K - Cerecor Inc. (0001534120) (Filer)
424B5 - Cerecor Inc. (0001534120) (Filer)
3 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Cerecor Inc. (0001534120) (Issuer)
4 - Cerecor Inc. (0001534120) (Issuer)